1. Home
  2. SAGE vs BOC Comparison

SAGE vs BOC Comparison

Compare SAGE & BOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • BOC
  • Stock Information
  • Founded
  • SAGE 2010
  • BOC 2009
  • Country
  • SAGE United States
  • BOC United States
  • Employees
  • SAGE N/A
  • BOC N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • BOC
  • Sector
  • SAGE Health Care
  • BOC
  • Exchange
  • SAGE Nasdaq
  • BOC Nasdaq
  • Market Cap
  • SAGE 462.2M
  • BOC 482.5M
  • IPO Year
  • SAGE 2014
  • BOC 2017
  • Fundamental
  • Price
  • SAGE $5.61
  • BOC $14.30
  • Analyst Decision
  • SAGE Hold
  • BOC Buy
  • Analyst Count
  • SAGE 19
  • BOC 3
  • Target Price
  • SAGE $11.53
  • BOC $20.00
  • AVG Volume (30 Days)
  • SAGE 1.1M
  • BOC 126.7K
  • Earning Date
  • SAGE 02-12-2025
  • BOC 11-12-2024
  • Dividend Yield
  • SAGE N/A
  • BOC N/A
  • EPS Growth
  • SAGE N/A
  • BOC N/A
  • EPS
  • SAGE N/A
  • BOC N/A
  • Revenue
  • SAGE $106,399,000.00
  • BOC $105,014,906.00
  • Revenue This Year
  • SAGE N/A
  • BOC $13.57
  • Revenue Next Year
  • SAGE $122.78
  • BOC $7.47
  • P/E Ratio
  • SAGE N/A
  • BOC N/A
  • Revenue Growth
  • SAGE 837.60
  • BOC 11.51
  • 52 Week Low
  • SAGE $4.62
  • BOC $12.41
  • 52 Week High
  • SAGE $28.26
  • BOC $16.99
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 50.27
  • BOC 39.12
  • Support Level
  • SAGE $4.94
  • BOC $14.17
  • Resistance Level
  • SAGE $5.91
  • BOC $15.60
  • Average True Range (ATR)
  • SAGE 0.36
  • BOC 0.36
  • MACD
  • SAGE 0.02
  • BOC -0.09
  • Stochastic Oscillator
  • SAGE 69.07
  • BOC 9.09

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About BOC Boston Omaha Corporation

Boston Omaha Corp is a us-based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. They generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.

Share on Social Networks: